Drug intelligence / Profile preview

cypher-002

Development stage: Preclinical
Lead developer: RION
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

Cypher-002 is an investigational exosome-based therapeutic developed by Rion. It is part of Rion's exosome drug delivery platform and is currently in preclinical development. The specific mechanism of action, molecular targets, and intended therapeutic indications for Cypher-002 have not been publicly disclosed as of the latest available information. Exosomes are small extracellular vesicles involved in intercellular communication and are being explored as vehicles for drug delivery or regenerative therapies[1][4].

Beyond the preview

Go deeper on cypher-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cypher-002.

Explore the full profile